North America Obesity Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Pharmaceuticals, Surgical Procedures, Behavioral Therapy, Medical Devices), By End User (Hospitals, Clinics, Home Care), By Demographics (Adults, Children, Adolescents), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), and North America Obesity Treatment Market Size Insights, Industry Trends, Forecast to 2035

North America Obesity Treatment Market Size Insights Forecasts to 2035

• The North America Obesity Treatment Market Size Was Estimated at USD 23.5 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 15.3% from 2025 to 2035
• The North America Obesity Treatment Market Size is Expected to Reach USD 112.5 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The North America Obesity Treatment Market Size is anticipated to reach USD 112.5 Million by 2035, growing at a CAGR of 15.3% from 2025 to 2035. The market is driven by the growing prevalence of obesity, rapid uptake of GLP-1 therapies, increasing numbers of bariatric procedures and high levels of clinical integration for advanced weight-management solutions.

Market Overview

Obesity treatment contains all medical and therapeutic interventions that work on eliminating excess body fat, thus making health better, preventing diseases that are related to obesity, and elevating life quality in general. Every single treatment plan is customised in every detail and in most cases, a combination of different approaches is applied to them. Among the various treatment options, medications such as Wegovy and Zepbound imitate gut hormones to inform the brain about the feeling of satiety and, at the same time, delay the process of gastric emptying. The treatment for severe obesity can involve the methods of physically restricting stomach size, such as surgery or intestinal bypass.

In January 2026, Eli Lilly will start new research and development, and the company will be able to provide large quantities of its long-awaited new weight-loss pill for several countries almost at the same time as it is expected to get the U.S. approval in the next few months.

The FDA has made use of priority review vouchers to expedite the market entry of next-generation drugs, thus making new obesity treatments available faster in return for the companies providing lower commercial prices. An increasing acknowledgement of obesity as a chronic disease is resulting in better insurance coverage and reimbursement policies, which, in turn, are improving patients' access to advanced therapies.

Report Coverage

This research report categorizes the market for the North America Obesity Treatment Market Size based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America Obesity Treatment Market Size. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America Obesity Treatment Market Size.

Driving Factors

The obesity treatment market in North America is driven by the rise in obesity cases, which is accompanied by an increase in metabolic co-morbidities, and this has resulted in the need for pharmacological treatment that is supported by clinical trials to provide and sustain significant weight losses. The main reason for this change is the very high and constantly increasing rate of obesity. The Centers for Disease Control and Prevention (CDC) proclaimed that during the period from August 2021 to August 2023, the adult obesity rate in the U.S. was above 42%. This high prevalence is the reason why the demand for effective treatment solutions is being directly increased.

Restraining Factors

The obesity treatment market in North America is restrained by high treatment costs, limited insurance coverage, and long-term therapy needs, which are among the major reasons that deter patients from receiving treatment. Some treatments involve risks of side effects or complications, and previous incidents regarding the safety of weight-loss drugs have left patients and doctors reluctant to adopt these treatments. A great many medical practitioners do not receive adequate training in the management of obesity, and the limited time available for consultations may prevent the doctor from discussing the patient's Sipping issue.

Market Segmentation

The North America Obesity Treatment Market Size share is categorised into treatment type, end user, demographics, and distribution channel.

• The pharmaceuticals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The North America Obesity Treatment Market Size is segmented by treatment type into pharmaceuticals, surgical procedures, behavioral therapy, medical devices. Among these, the pharmaceuticals segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by the available treatment options, being friendly for all and can be utilised either separately or along with making changes in living style. Obesity is gradually acknowledged as a chronic metabolic disorder rather than just a lifestyle choice, and thus, the prescribing rates by general practitioners are increasing.

• The hospitals segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on end user, the North America Obesity Treatment Market Size is segmented into hospitals, clinics, home care. Among these, the hospitals segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is driven by its capability of offering multidisciplinary teams, such as surgeons, nutritionists, and experts from different fields. This setup is conducive to a huge range of treatments, from surgery and behavioral therapy to the ability of carrying out complex surgeries and providing extensive, multi-specialty care that is backed up by advanced technology and skilled professionals.

• The adults segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The North America Obesity Treatment Market Size is segmented by demographics into adults, children, adolescents. Among these, the adults segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by the higher prevalence of obesity-related complications in adults, combined with their greater inclination to get medical attention, which is the main reason for this trend. In the US, around 42% of adults are considered obese, while only about 20% of children fall into this category. Moreover, almost 58% of obese adults have high blood pressure and 23% are suffering from type 2 diabetes, which makes it really important to get medical treatment right away.

• The online pharmacies segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on distribution channel, the North America Obesity Treatment Market Size is segmented into online pharmacies, retail pharmacies, hospital pharmacies. Among these, the online pharmacies segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is driven by supplying a wide variety of medicines, and at the same time keeping the customers' privacy and convenience as the top priority. They target an increasing population that likes to treat their health problems right in their homes. The boom of telehealth services has also made their position stronger, as it has facilitated easy access to prescriptions for patients.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America Obesity Treatment Market Size, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                                                              

• Eli Lilly and Company
• Pfizer
• Rhythm Pharmaceuticals
• Currax Pharmaceuticals
• VIVUS LLC
• Medtronic
• Boston Scientific Corporation
• Johnson & Johnson Services, Inc.
• Allurion Technologies
• Altimmune
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In January 2026, Novo Nordisk launched oral Wegovy weight-loss treatment across the US. The first oral GLP-1 treatment approved for chronic weight management in adults with obesity or overweight with related medical conditions.

Market Segment

This study forecasts revenue at the North America, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the North America Obesity Treatment Market Size based on the below-mentioned segments:

North America Obesity Treatment Market Size, By Treatment Type

• Pharmaceuticals
• Surgical Procedures
• Behavioral Therapy
• Medical Devices

North America Obesity Treatment Market Size, By End User

• Hospitals
• Clinics
• Home Care

North America Obesity Treatment Market Size, By Demographics

• Adults
• Children
• Adolescents

North America Obesity Treatment Market Size, By Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies